期刊文献+

1012例乙肝病毒患者HBV P区基因位点变异分析 被引量:8

Mutation Analysis of P Region Gene Locus of HBV from 1012 Patients
下载PDF
导出
摘要 目的研究人群中乙肝病毒(HBV)P区位点突变发生的频率和特点。方法通过高保真PCR扩增1 012例乙肝病毒患者HBV的P区基因片段,采用双脱氧末端终止法进行测序,分析HBV P区169、173、180、181、184、194、202、204、233、236和250共11个位点的变异情况。结果 HBV P区204和180位点突变频率较高;其次是181和236位点;其余位点突变频率很低。在男性患者中,204位点和180位点突变率相对较高;女性患者中存在同样的情况。30岁以下患者与31至60岁患者相比较,181位点变异率差异较大(P<0.01)。其余无显著差异(P>0.05)。结论 HBV P区位点突变主要集中在180、181、204和236位点。不同性别的患者中,HBV P区基因突变率尚不具有统计意义上的显著差异。不同年龄段的患者中,HBV P区181位点的突变率具有极显著差异。通过测序技术检测P区位点的突变,可以全面反映P区位点的变异情况,为临床用药和抗病毒新药研发提供重要依据。 Objective To study the mutation frequency and characteristics of hepatitis B virus (HBV) P region in population. Methods P region gene fragments of HBV from 1012 patients were amplified using high fidelity PCR amplification and sequenced by dideoxy chain termination method. Mutation ofll locus including 169,173,180,181,184, 194,202,204,233,236 and 250 in P region were analyzed. Results Mutation rates of point 204 and 180 are the highest and points 181 and 236, followed. Others are at low mutation rates. In both male and female patients, mutation rates in point 204 and 180 are higher than others. The mutation rate in 181 is significantly different between patients below 30 years old and those from 31 to 60 years old. Others are no significantly difference. Conclusion Mutations mainly concentrate in points of 180,181,204 and 236 in HBV P region, and lower percentages of variation exist in the other points. Mutation rates of HBV P region have no statistical significance in patients of different gender. Mutation rates in point 181 have significantly difference in patients of different ages. Detecting mutation in P region sites through sequencing reflects the variation of P region sites and provides important information for development of new anti-virus drugs.
出处 《健康研究》 CAS 2011年第1期17-20,共4页 Health Research
关键词 乙肝病毒 P基因 耐药 突变 hepatitis B virus P gene drug resistance Mutation
  • 相关文献

参考文献12

二级参考文献76

  • 1孙庆丰,吕勇,徐道振,蓝贤勇,刘景院,孙雪娟.乙型肝炎病毒e抗原及DNA载量对慢性乙型重型肝炎预后的影响[J].中华肝脏病杂志,2006,14(6):410-413. 被引量:32
  • 2Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9):643-646. 被引量:829
  • 3吴云忠,赵凤林,张春泽,李明慧,谢尧.慢性重型乙型肝炎转归相关因素及抗病毒治疗研究[J].中华实验和临床病毒学杂志,2007,21(2):120-122. 被引量:22
  • 4Adziyannis SJ.Tassopoulos NC,Heathcote EJ,et al.Long-term therapy with adefovir dipivoxil for HBeAg-negative chronichepatitis B [J].N Engl Jmed,2005,352(26):2 673-2 681
  • 5Ahmed SNS,Tavan D. Early detection of viral resistance by determination of hepatitis B virus polymerase mutantions in patients treated by lamivudine for chronic hepatitis B[J].Hepatology,2000,32: 1 078-1 088
  • 6Tsubota A. Lamivudine therapy for spontaneously occurring severe a-cute exacerbation in chronic hepatitis B virus infection:a preliminary study [ J ]. Am J Gastroenterol, 2001,96 (2) : 557 - 62.
  • 7Tsang SW. Lamivudine treatment for fuhninant hepatic failure due to acute exacerbation of chronic hepatitis B infection[ J]. Aliment Pharmacol Ther, 2001,15(11): 1737 -44.
  • 8Anna SL, Fabien Z, Stephen L, et al. Antiviral drug - resistant HBV: Standardization of nomenclature and assays and recommenda-tions for management [ J ]. Hepatology, 2007,46 ( 1 ) : 254 - 265.
  • 9Ting - Tsung C, Robert G, Robert D M, et al. A comparison of Entecavir and Lamivudine for HBeAg- positive chronic hepatitis B[ J]. N Engl J Med, 2006, 354:1001 - 10.
  • 10Guangbi Ya. Entecavir is a potent anti - HBV drug superior to lamivudine: experience from clinical trials in China[ J]. Journal of Antimicrobial Chemotherapy,2007, 60:201 - 205.

共引文献256

同被引文献42

引证文献8

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部